Favipiravir

Summary

Favipiravir (CHEMBL221722) is an approved small-molecule antiviral drug (ATC J05AX27); indicated across 9 conditions including viral infectious disease and influenza.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AX27
• Indications: 9 conditions
• Clinical trials: 61
• Chemistry: 157.1 Da · C5H4FN3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL221722
Name	Favipiravir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	492405
ChEBI	CHEBI:134722
ATC	J05AX27
Molecular formula	C5H4FN3O2
Molecular weight	157.1
InChIKey	ZCGNOVWYSGBHAU-UHFFFAOYSA-N

SMILES: C1=C(N=C(C(=O)N1)C(=O)N)F

IUPAC name: 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide

ChEBI definition: A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.

Pharmacological roles (ChEBI): antiviral drug, anticoronaviral agent, EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor.

Also known as: Avigan, Favipiravir, T-705, FAVIPIRAVIR, favipiravir, Favipiravir; Avigan

Patent coverage: 1,957 distinct patent families (4,309 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,609 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: RNA-directed RNA polymerase.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	3	MONDO:0005108	EFO:0000763
influenza	3	MONDO:0005812	EFO:0007328
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
Ebola hemorrhagic fever	2	MONDO:0005737	EFO:0007243
Lassa fever	2	MONDO:0005820	EFO:0007338
liver disorder	1	MONDO:0005154	EFO:0001421
viral pneumonia	1	MONDO:0006012	EFO:0007541
infectious disease	1	MONDO:0005550	EFO:0005741

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 61.

Phase distribution

Phase	Trials
PHASE3	21
PHASE2	18
PHASE2/PHASE3	7
Not specified	6
PHASE1/PHASE2	4
PHASE1	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04359615	PHASE4	UNKNOWN	Favipiravir in Hospitalized COVID-19 Patients
NCT05502081	PHASE4	COMPLETED	Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
NCT06212336	PHASE2/PHASE3	RECRUITING	ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
NCT02008344	PHASE3	COMPLETED	Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
NCT02026349	PHASE3	COMPLETED	Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
NCT04319900	PHASE2/PHASE3	UNKNOWN	Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia
NCT04336904	PHASE3	UNKNOWN	Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
NCT04349241	PHASE3	COMPLETED	Efficacy and Safety of Favipiravir in Management of COVID-19
NCT04351295	PHASE2/PHASE3	COMPLETED	Efficacy of Faviprevir in COVID-19 Treatment
NCT04373733	PHASE3	COMPLETED	Early Intervention in COVID-19: Favipiravir Verses Standard Care
NCT04402203	PHASE2/PHASE3	UNKNOWN	Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
NCT04425460	PHASE3	UNKNOWN	A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19
NCT04434248	PHASE2/PHASE3	UNKNOWN	An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT04464408	PHASE2/PHASE3	COMPLETED	Favipiravir Therapy in Adults With Mild COVID-19
NCT04501783	PHASE3	COMPLETED	Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
NCT04529499	PHASE3	TERMINATED	Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
NCT04542694	PHASE3	COMPLETED	Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT04558463	PHASE3	UNKNOWN	The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19
NCT04600895	PHASE3	COMPLETED	The Prevent Severe COVID-19 (PRESECO) Study
NCT04600999	PHASE3	COMPLETED	Clinical Trial of Favipiravir Treatment of Patients With COVID-19
NCT04613271	PHASE3	COMPLETED	Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
NCT04694612	PHASE3	UNKNOWN	Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
NCT04784559	PHASE3	TERMINATED	Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT04818320	PHASE3	COMPLETED	Favipiravir in High-risk COVID-19 Patients
NCT04828564	PHASE2/PHASE3	UNKNOWN	Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
NCT04981379	PHASE3	COMPLETED	Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
NCT05014373	PHASE3	UNKNOWN	Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19
NCT05185284	PHASE3	COMPLETED	Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT05279235	PHASE3	TERMINATED	Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
NCT05417997	PHASE3	COMPLETED	Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
NCT04746183	PHASE1/PHASE2	RECRUITING	AGILE (Early Phase Platform Trial for COVID-19)
NCT05041907	PHASE2	RECRUITING	Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT05648448	PHASE2	RECRUITING	A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
NCT06488300	PHASE2	RECRUITING	Assessing Antiviral Treatments in Early Symptomatic RSV
NCT06860334	PHASE2	NOT_YET_RECRUITING	UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF
NCT01068912	PHASE2	COMPLETED	Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
NCT01728753	PHASE1/PHASE2	COMPLETED	T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
NCT02329054	PHASE2	COMPLETED	Efficacy of Favipiravir Against Ebola (JIKI)
NCT02662855	PHASE2	COMPLETED	Efficacy of Favipiravir Against Severe Ebola Virus Disease
NCT02739477	PHASE2	TERMINATED	Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).